Quick Facts

• May be administered for the management of nausea and vomiting.
• Used for the relief of discomfort associated with certain gastrointestinal disorders.
• Contributes to addressing symptoms like indigestion and heartburn.

Farcotilium is an available therapeutic option used for the management of symptoms such as nausea and vomiting. These conditions are often associated with various gastrointestinal disorders. The medication may also be administered to provide relief from other forms of upper digestive discomfort, including indigestion and heartburn. Its use in addressing these symptoms is supported by clinical experience.

Farcotilium is the trade name for Domperidone, a compound used in various regions to address specific gastrointestinal motility issues and symptoms. It is important to note that the use and regulatory status of this drug vary by location.

Who Can and Cannot Use Farcotilium?

The eligibility to use Farcotilium is strictly defined by regulatory authorities based on age, weight, and pre-existing medical conditions.

Eligibility and Non-Eligibility Status

Absolute Contraindications

Use of Farcotilium is absolutely contraindicated in patients with specific comorbidities. These exclusions include moderate or severe hepatic impairment, prolactin-releasing pituitary tumour (prolactinoma), and specific cardiac conduction abnormalities (QTc prolongation). It is also prohibited in patients with underlying cardiac diseases like congestive heart failure or significant electrolyte disturbances. The medicine must also not be used if stimulation of gastrointestinal motility would be harmful, such as in cases of haemorrhage, obstruction, or perforation [1.1, 4.3].

Conditional Use and Restrictions

Eligibility is further constrained by physiological status. Patients with severe renal impairment require a reduction in dosing frequency [4.3]. For pregnancy, use is conditional, permitted only when the therapeutic benefit justifies the risk. The drug is excreted in human milk, requiring that breastfeeding must be discontinued or therapy must cease [1.4, 3.5]. Older adults (over 60 years) are noted to have a higher observed risk of serious cardiac events [1.4].

Interactions with other medicines and products

This section outlines the clinically significant interactions of Farcotilium as documented in official government regulatory information.

Farcotilium's interaction profile is primarily defined by its effects on drug-metabolizing enzymes and transport proteins, necessitating constraints on co-administration with other substances.

Interaction Classifications and Restrictions

Official Interaction Statements

• Co-administration of Farcotilium with strong CYP3A4 inhibitors (e.g., Ketoconazole) is strictly prohibited as it results in severe exposure modification.
• Farcotilium must be administered with a 4-hour separation period from antacids to prevent documented interference with its absorption rate.
• The use of herbal products, specifically St. John's wort, is explicitly restricted due to its potent enzyme induction properties which reduce drug efficacy.

This official interaction profile defines requirements for prescribers and patients to mitigate pharmacokinetic and pharmacodynamic risks arising from concurrent therapy.

The Pharmacodynamics of Farcotilium

Farcotilium functions as a selective antagonist (blocker) of Dopamine mathbfD2 and mathbfD3 receptors in the peripheral nervous system and selected central areas.

Its antiemetic action occurs in the Chemoreceptor Trigger Zone (CTZ), located outside the blood-brain barrier. Antagonism of mathbfD2/D3 receptors here prevents the neurotransmitter dopamine from activating the signaling cascade necessary to initiate the emetic reflex.

The drug also targets mathbfD2 receptors on the enteric nervous system, where dopamine typically exerts an inhibitory control over smooth muscle contraction. By blocking this signal, Farcotilium increases the tone and amplitude of smooth muscle contractions and elevates the lower esophageal sphincter (LES) pressure. This action results in a reduction in gastric transit time and modification of movement in the upper gastrointestinal tract.

Antagonism of the mathbfD2 receptor also extends to the pituitary gland. Removal of dopamine's inhibitory control over the lactotroph cells leads to the release of prolactin into the bloodstream, a resulting pharmacodynamic consequence of the mechanism.

Farcotilium is administered solely via the oral route, available primarily as 10 mg tablets or an oral suspension (1 mg/ml). Proper use is governed by a strict regimen focused on the lowest effective dose for the shortest duration necessary. The standard single administration is 10 mg, which may be taken up to three times per day, resulting in a maximum total daily dose of 30 mg. It is required that patients observe a minimum interval of 8 hours between each administration. The treatment course is designed to be short-term; the duration of use must generally not exceed seven consecutive days.

Administration instructions specify that the medicine should be taken before meals (15 to 30 minutes prior). This timing is crucial for optimal absorption, and the tablets must be swallowed whole without chewing. If an administration is missed, the patient must omit that dose and resume the regular schedule, ensuring no attempt is made to double the quantity taken.

Official guidance dictates that the 10 mg regimen applies only to adolescents aged 12 years and older who weigh 35 kg or more. Furthermore, patients with severe renal impairment must have the dosing frequency reduced to once or twice daily to maintain the correct usage pattern.

Research Evidence / Overview of Studies for Farcotilium

This overview describes the types of research conducted on the use of Farcotilium (Domperidone) and what the findings, according to regulatory and scientific bodies, indicate about the evidence landscape.

Evidence for Use in Acute Nausea and Vomiting

Research exploring short-term symptom changes has primarily involved short-term, randomized controlled trials (RCTs). These studies was evaluated in contexts such as children experiencing acute digestive upset or patients receiving certain treatments that cause systemic or functional imbalance. Researchers monitored outcomes describing episodic or acute changes, such as the frequency of vomiting and nausea episodes over a defined time interval.

Findings describe patterns observed in the studies; however, results apply only to the populations studied, and certainty remains low in some groups. For example, some controlled trials focusing on children with acute digestive upset reported mixed or inconsistent findings in measured outcomes. Follow-up durations were limited, as the studies primarily focused on research exploring short-term symptom changes. Data for certain groups, such as very young children, remain insufficient, and the research provides context but not individual predictions about how a child may respond.

Evidence for Gastrointestinal Motility Symptoms

Research examining temporary physiological imbalance in the upper digestive system was evaluated in several types of studies, including systematic reviews, short-term RCTs, and large observational patient registries. This research examined conditions marked by functional limitations, such as gastroparesis and functional dyspepsia.

The studies monitored outcomes related to physical discomfort and functional imbalance, such as changes in symptom severity scores (e.g., GCSI) and functional measures (e.g., Gastric Emptying Time). Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations.

Certainty remains low for some long-term applications. There is limited information for long-term outcomes regarding symptoms of functional dyspepsia and some reflux conditions. Older studies included in systematic reviews sometimes featured methodological limitations, such as modest sample sizes or less rigorous control procedures, meaning evidence quality varies across studies.

Common questions about Farcotilium (FAQ)

Q: Does it make you sleepy?

According to the official product information, drowsiness (also called somnolence) is a common undesirable effect reported during clinical studies with Farcotilium. This potential side effect is noted in the official documentation. Fatigue, or feeling very tired, is also commonly listed in the regulatory documents.

Q: Can children 2 years old use it?

The official regulatory documents specify the age groups for which Farcotilium is approved. The medication is typically not approved for use in children under a specific minimum age (e.g., 3 years old or 12 years old), depending on the indicated condition. The approved minimum age for use is detailed in the specific regulatory labeling.

Storage Guidelines

Store Farcotilium at room temperature, away from excess heat and moisture. Keep all medications in their original containers, tightly closed, and stored out of the reach of children and pets. Do not store this medicine in the bathroom or near a sink.

Disposal Instructions

The most advisable method for disposing of unused or expired Farcotilium is through a community drug take-back program.

If a take-back program is unavailable, you can dispose of the medication in your household trash, ensuring it is prepared correctly. Mix the medicine (do not crush tablets) with an unappealing substance, such as dirt, cat litter, or used coffee grounds. Place the mixture into a sealed plastic bag or other container to prevent leakage. Before discarding, scratch out all personal information from the prescription label on the empty packaging to protect your privacy. Do not flush this medication down the toilet unless specifically instructed to do so by your healthcare provider or the product information.